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Abstract
Objectives—Dietary intake of vitamin D and calcium may be related to risk of breast cancer,
possibly by affecting mammographic density. However, the few studies that have evaluated the
association between these nutrients and mammographic density in postmenopausal women have had
inconsistent results.
Methods—We conducted a cross-sectional analysis in 808 participants of the Mammogram Density
Ancillary Study of the Women's Health Initiative. Mammographic percent density was measured
using baseline mammograms taken prior to randomization of participants in the intervention trials.
Vitamin D and calcium intake was assessed with a validated food frequency questionnaire and an
inventory of current supplement use both completed at baseline.
Results—After adjustment for age, body mass index, regional solar irradiance and other factors,
we did not find a relationship between vitamin D or calcium intake and mammographic density.
Mean mammographic percent density in women reporting total vitamin D intakes of <100, 100-199,
200-399, 400-599, ≥600 IU/day were 5.8%, 10.4%, 6.2%, 3.8%, and 5.1%, respectively (P-trend =
0.67). Results in women reporting total calcium intake of <500, 500-749, 750-999, 1000-1199, and
≥1200 mg/day were 7.3%, 4.9%, 7.3%, 6.9%, and 7.l%, respectively (P-trend = 0.51). We did not
observe effect modification by overall level of mammographic density or solar irradiance, but
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supplemental vitamin D use was associated with lower density in younger women (P-
interaction=0.009).
Conclusions—These findings do not support a relationship between dietary vitamin D or calcium
intake and mammographic density in postmenopausal women. Additional studies should explore
these associations in women of different ages and in relation to serum vitamin D levels.
Keywords
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INTRODUCTION
Mammographic density has been identified as a strong predictor of breast cancer risk. Relative
risks of breast cancer for women with high percent density (i.e., ≥ 50-75% fibro-glandular
tissue) compared to those with relatively lower density (i.e., < 25%) have ranged from 2.0-6.0
in recent studies.1,2 These associations appear to apply to both premenopausal and
postmenopausal breast cancer. Given the consistency of evidence and the strong magnitude of
the associations observed, mammographic density may be an intermediate biomarker of breast
cancer and has been used as a surrogate endpoint for breast cancer risk in some studies.1,3
Some evidence suggests that vitamin D may be inversely related to risk of breast cancer.4,5 In
vitro studies indicate that vitamin D can inhibit cell proliferation and promote apoptosis and
cell differentiation in breast tumor tissue.6-8 Results from observational studies of vitamin D
and breast cancer risk have been inconsistent. While some studies have found high dietary
vitamin D intake and/or high 25-hydroxyvitamin D levels to be protective against risk of
postmenopausal breast cancer,9-15 others have reported a borderline association16 or no
association.17-22 Studies in premenopausal women have more consistently reported an inverse
relationship,18,20,23,24 but overall results have also be inconclusive. A large randomized trial
in the Women's Health Initiative, which compared daily intake of 1000 mg of elemental calcium
plus 400 IU of vitamin D3 per day to placebo, did not find that supplementation reduced risk
of postmenopausal breast cancer over 7 years.21 A second smaller trial of postmenopausal
women reported that overall cancer incidence was significantly reduced after 4 years of
supplementation with 1400-1500 mg of elemental calcium plus 1100 IU of vitamin D3 per day,
2 but too few cases of breast cancer (n=19) occurred during follow-up to separately evaluate
effect of intervention on this cancer.
Only a small number of studies have considered whether vitamin D and calcium intake may
be related to breast cancer risk through a relationship to mammographic density. Results have
been inconsistent, with inverse relationships between dietary vitamin D, 25-hydroxyvitamin
D (25(OH)D) levels and/or calcium and postmenopausal mammographic density observed in
some26-30 but not all31-36 studies. Results from these analyses have raised several interesting
questions warranting further investigation. For example, it is not clear whether vitamin D and
calcium from foods and from supplements are similarly related to mammographic density. In
addition, factors such as regional solar irradiance, season, and duration of supplement use may
modify this relationship and yet have been infrequently considered. Therefore, we conducted
a cross-sectional analysis of the relationship between mammographic density and dietary
vitamin D and calcium intake in the Women's Health Initiative, a diverse and well-characterized
population of postmenopausal women.
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The Women's Health Initiative randomized clinical trials of postmenopausal hormones have
been described in detail previously.37-39 Briefly, between 1993 and 1998, women age 50-79
years of age were recruited through direct mailing campaigns and media awareness programs.
Enrollments were made at 40 clinical centers throughout the US. Major ineligibility criteria
for the trials included medical conditions likely to result in death within 3 years, previous
history of breast or other cancers (except non-melanoma skin cancer), and conditions likely to
interfere with adherence and retention, including alcoholism and dementia. Ultimately, 16,608
women who had not had a hysterectomy were randomized to 0.625 mg conjugated equine
estrogen plus 2.5 mg medroxyprogesterone acetate per day in a single table or a similar placebo
(E+P trial). An additional 10,739 women without a uterus were randomized to 0.625 mg
conjugated equine estrogen daily or a similar placebo (E-alone trial).
At baseline enrollment visits prior to randomization, participants completed questionnaires that
assessed a variety of demographic, reproductive, behavioral and health factors. Participants
were required to have evidence of a screening mammogram within 6 months prior to
randomization or were referred for a screening mammogram before they were randomized.
The study protocol was approved by institutional review boards at each participating
institution.
WHI Mammogram Density study
The Mammogram Density Ancillary Study of the WHI hormone trial has been described in
detail previously.40 Briefly, this ancillary study enrolled women from both the E+P and E-
alone trials to evaluate the effect of postmenopausal hormones on mammographic density.
Fifteen of the 40 clinical centers agreed to participate. Women who had a baseline mammogram
taken prior to randomization and at least one follow-up mammogram 1-2 years later were
eligible to join. The WHI Clinical Coordinating Center identified eligible women and selected
those for inclusion in this ancillary study using a stratified random sampling protocol, with the
goal of enrolling equal numbers of non-Hispanic white, African American, Hispanic, and Asian
American women. Among E+P trial participants, 214 of the 233 women sampled from those
assigned to E+P and 223 of the 240 women sampled from those assigned to placebo agreed to
join in the mammogram density study. Complete mammogram data showing no evidence of
invasive breast cancer were received from 202 women assigned to E+P and 211 assigned to
placebo. Among E-alone trial participants, 220 of the 234 women sampled from those assigned
to E-alone and 238 of the 264 women sampled from those assigned to placebo agreed to join
in the mammogram density study. Complete mammogram data showing no evidence of
invasive breast cancer were received from 209 women assigned to E-alone and 226 assigned
to placebo. Ultimately, 808 women were included in the present analysis.
Assessment of mammographic density
After receiving informed consent, mammograms from each participant were requested from
their individual mammography provider, blinded as to participant identification, and then sent
to the University of North Carolina for digitizing. Mammograms were taken within the 6
months prior to randomization for 805 (99.6%) women; for the other 3 (0.4%) women, the
mean time between mammogram and randomization was 12 months.
Digitizing of films was performed on a Lumisys 85 laser digitizer with a maximum resolution
of approximately 50 μm and 12-bit depth, with the digitizer recalibrated between sessions. A
standard data-averaging method was used to convert raw image files to bitmap format for
display and measurement of mammographic density. For each film, a unique serial number,
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the date of exam, laterality and view were recorded. The technique used to assess
mammographic density has been validated previously41 and used a computer-assisted
interactive thresholding technique with software from the Imaging Research Program
(Sunnybrook Health Science Center, Toronto, Ontario, Canada).
Mammograms were sorted separately for 2 trained observers (CM, JP), who both reviewed all
films. Inter-observer reliability for measuring percent density was assessed before the study
began and found to be very high (i.e., intraclass correlation coefficients >0.92). Observers were
blinded to participant identification, randomization status, the timing of the mammogram
(baseline vs. follow-up), result from the other observer, and results of other mammograms from
the same woman. The craniocaudal view of the right breast was used if available, otherwise
the same view from the left breast was used. Investigators determined the breast edge and
noncontinguous areas of mammographic density. The total area of breast and the total
combined area of mammographic density were both calculated (pixels), and then the latter was
divided by the former to calculate percent density. Each participant's density was then
calculated as the mean of the estimates of percent density from the 2 readers.
Assessment of vitamin D and calcium intake and other factors
At their baseline clinic visit, participants completed a semiquantitative food frequency
questionnaire (SFFQ) designed for the Women's Health Initiative and validated in this
population.42 Participants were asked to report their usual intake of 122 foods or food groups
in the 3 previous months, with response options ranging from never or less than once per month
to ≥2 times per day (≥6 times per day for beverages). Women were also asked to specify their
usual portion size compared to a stated medium size serving for each food. Additional questions
asked about usual cooking method, fats added during cooking, and usual intake of specific
food groups.
Vitamin D and calcium intakes from food sources were calculated by multiplying the nutrient
content of the specified portion size of each food (University of Minnesota Nutrient Coding
Center nutrient database) by its frequency of consumption and summing the contributions of
all foods. Nutrient intakes were adjusted for total energy intake, also measured by SFFQ, by
the residual method.43
Information on the use of vitamin and mineral supplements, including those containing vitamin
D and calcium, was also collected at the baseline clinic visit. Women were interviewed about
their use of supplements by trained interviewers using a standard questionnaire. Participants
were also asked to bring all supplements they were currently taking to their clinic interview,
where the interviewer recorded the dose, frequency (pills per week), and duration (months and
years) of use for multivitamins, multivitamin-mineral, and single supplements. Interviewers
also directly recorded the ingredients of all supplements provided. Only supplements used once
per week or more were recorded.
Study questionnaires completed during baseline visits were used to assess breast cancer risk
factors, including age, race/ethnicity, previous use of hormone therapy and oral contraceptives,
education, alcohol intake, participation in physical activity, history of smoking, and age at
menarche. Weight and height were measured directly and used to calculate body mass index
(weight (kg) / height (m) squared). Annual evel of solar irradiance in Langleys (gm-cal) per
cm2 at each clinical center was estimated using measurements from the US Weather Bureau
and were adapted for use in the WHI.44
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All analyses were based on mammograms collected at baseline before study participants were
randomized to hormone therapy, dietary modification or calcium and vitamin D (i.e., CaD trial)
interventions. We excluded from analysis 40 women with implausible calorie intake (<600 and
>5000 kcal/day). Differences in mean total vitamin D and total calcium intake by participant
characteristics at baseline were compared, along with p-values from F-tests in a linear model
adjusted for age and ethnicity. The study population was divided into categories of nutrient
intake (calcium and vitamin D), and to be consistent with previously published work,40 we
present arithmetic means. Since mammographic density of our sample was skewed, statistical
tests were performed on the log scale across categories of nutrient intake using linear models.
This analysis was repeated for vitamin D from food sources and supplements separately, and
for the three aspects of calcium intake (i.e., total, and food and supplements separately). We
also cross-classified participants by collapsed categories of vitamin D and calcium level, and
assessed interaction between nutrients using a multiplicative interaction term in the
multivariable model.
In addition to adjusting for age, we used multivariable analyses to adjust for factors determined
to be important confounders of the nutrient -- mammographic density relationship and those
that have been identified as confounders in previous studies in the literature. We evaluated
three specific multivariable models. Model 1 was adjusted for factors associated with breast
cancer, mammographic density and/or vitamin D and calcium intake. These included: age
(models included categories of 50-59, 60-69, 70-79 years, and a continuous variable); race/
ethnicity (Asian/Pacific Islander, Black, Hispanic; White not of Hispanic origin); duration of
self-reported past hormone therapy use at baseline (0, <5, 5-<10, ≥10 years), education (school
after high school); body mass index (models included categories of <25, 25-<30, ≥30 kg/m2
and a continuous variable); alcohol intake (0, ≤1, >1 drink per day); hours per week of
moderate-to-strenuous physical activity (tertiles); smoking status (never, former, current); age
at menarche (≤12, 12-13, ≥14 years); parity (0, 1, 2, ≥3), family history of breast cancer (no,
yes); Gail risk score (models included tertiles of score and a continuous variable), duration of
oral contraceptive use (0, <5, 5-<10, ≥10 years), and total calories (models included tertiles of
intake and a continuous variable). We adjusted for hormone treatment assignment (E+P, E+P
placebo, E-alone, E-alone placebo) because, in addition to mammographic density, baseline
vitamin D and calcium intake varied by treatment arm. We also adjusted for multivitamin use
(no, yes) because previous studies have reported significant differences in behaviors related to
vitamin D level and mammographic density in women who do and do not use multivitamins.
Model 2 adjusted for all factors in model 1, and additionally, calcium and vitamin D were
adjusted for the effects of the other nutrient, and nutrients from food sources were also adjusted
for the effects of nutrients from supplements, and vice versa. Model 3 adjusted for all factors
included in models 1 and 2, and in addition controlled for factors associated with endogenous
vitamin D production including season of mammogram (winter, spring, summer, fall) and solar
irradiance at each participant's WHI clinic location (<350, 350-< 400, ≥400 Langleys). Models
1 through 3 were weighted to account for sampling design. Weights are inversely proportional
to the probability of being selected from the clinical trial into the Mammogram Density
Ancillary Study and are estimated from a logistic regression model. Predictor variables
included the sampling strata variables (i.e., race/ethnicity and hysterectomy status), age and
prior hormone use.
We investigated whether the effects of vitamin D (total, dietary and supplemental) and calcium
(total, dietary and supplemental) were modified by age, race/ethnicity, body mass index,
smoking status, duration of supplement use, alcohol use, and solar irradiance at each
participant's clinical center, as has been suggested by previous studies. Interactions were
assessed using multiplicative interaction terms in multivariable models. Interactions with p-
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values < 0.05 were judged to be statistically significant; two significant interactions were
expected due to chance.
To evaluate whether a nutrient-density relationship was more evident in women with higher
percent density, we classified women by overall category of mammographic percent density
at baseline (<1%, 1 – 9%, ≥ 10%). Finally, we conducted a subanalysis excluding women
reporting multivitamin use and those reporting hormone treatment at baseline.
RESULTS
Participant characteristics by mean total vitamin D and calcium intake are presented in table
1. Vitamin D and calcium intake were each significantly and positively associated with age,
education, and physical activity level. Intakes of both nutrients varied significantly by race/
ethnicity and by hormone trial. Vitamin D and calcium intakes were inversely related to level
of solar irradiance, and calcium intake varied by smoking status.
In multivariable models adjusting for age, smoking and breast cancer risk factors (model 1),
we did not observe a relationship between total intake of vitamin D and baseline
mammographic density (table 2). Mean percent mammographic density by increasing
categories of total vitamin D intake were 5.4%, 9.8%, 6.2%, 4.0% and 5.7%, respectively (P
for trend = 0.96). Results from models further adjusted for calcium intake (model 2) and for
Langleys and season of mammogram (model 3) were similar. We observed evidence of a
modest positive association between vitamin D from food sources and mammographic density
(P for trend = 0.05). Vitamin D supplement use was unrelated to mammographic density.
We did not find a relationship between mammographic percent density and total calcium intake,
calcium from foods sources only or calcium from supplements (table 2). For example, mean
mammographic percent density in women reporting total calcium intake of ≥1200 mg/day was
6.4% (95% CI = 4.7-8.1; P for trend = 0.42).
When total vitamin D and calcium intake were assessed together (table 3), we did not observe
an interaction between nutrients (P for interaction = 0.99). Density was lowest in women
reporting 200-399 IU/day of vitamin D and <750 mg/day of calcium (2.4%; 95% CI = 0.0–
5.7), and highest in those reporting <200 IU/day of vitamin D and 750-1199 mg/day of calcium
(10.5%; 95% CI = 7.2-13.8).
We stratified our participants by category of mammographic percent density at baseline to
evaluate whether a nutrient-density relationship was more evident among women with higher
mammographic density. Results are presented in table 4. Among women with density ≥10%,
we did not find either vitamin D or calcium intake to be significantly associated with mean
mammographic density. However, women taking vitamin D supplements had a modestly lower
mammographic density (P=0.09).
We assessed whether the nutrient-mammographic density relationship was modified by several
other factors. The effect of vitamin D supplement use was significantly modified by age (P-
interaction = 0.009), with supplement use associated with lower density among women aged
50-59 (mean, 95% CI = 6.7, 3.5-9.8 for supplement users vs. 9.0, 6.7 – 11.3 for non-users), but
not among older women. We did not observe evidence of effect modification by other factors,
including body mass index, race/ethnicity, alcohol use, duration of supplement use, and solar
irradiance (p-values all >0.05; results not shown). Furthermore, we did not find evidence that
the vitamin D-mammographic density relationship varied by season of mammogram, and there
was no seasonal variation in vitamin D intake, calcium intake, or mammographic density.
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Results from analyses limited to women not reporting multivitamin use (n = 579) were similar
to those of the main analysis; for example, mean percent mammographic density in women
reporting total vitamin D intake of <100, 100-150, 150-199 and ≥200 IU/day were 4.9%, 9.5%,
6.3% and 5.3%, respectively (P for trend = 0.40). Mean percent mammographic density in
women reporting total calcium intake of < 500, 500-749, 750-999 and ≥ 1000 mg/day were
7.6%, 6.2%, 9.4% and 5.9%, respectively (P for trend = 0.66). Results limited to women not
reporting hormone therapy use at baseline (n = 755) were also virtually identical to the main
analysis.
DISCUSSION
In our large population of postmenopausal women, we did not observe a relationship between
dietary intake of vitamin D and calcium and mean mammographic percent density prior to
randomization in the intervention trials. Adjustment for factors including solar irradiance and
season of mammogram did not alter these findings.
While some previous studies have observed a relationship between these nutrients and
postmenopausal mammographic density, results overall have been inconclusive. In a study of
a population at high risk for breast cancer, Tseng and colleagues (2007)30 reported a significant
50% lower risk of high breast density in women with high vitamin D intake (median = 737 IU/
day) compared to those reporting the lowest intake (median = 164 IU/day). Higher vitamin D
and/or calcium intake were also inversely related to high mammographic density in a two other
studies.26,27 In contrast, several other studies in a variety of other populations have not
observed relationships between mammographic density and intake of vitamin D28,31-33,35 or
calcium28,30-33,35 in postmenopausal women.
Inverse relationships between vitamin D, calcium and mammographic density have been more
consistently observed in studies of premenopausal women.28,31,32,35,45 Differences in finding
by menopausal status may be in part due to the complex interplay between these nutrients and
insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3). Evidence from
laboratory studies suggests that vitamin D and calcium may interact with IGF-1 and IGFBP-3
through a variety of mechanisms,46 many of which may affect breast cell proliferation and
breast cancer development.45 In a study of 771 premenopausal women, Diorio and colleagues
(2006)45 found that the inverse relationships between vitamin D and calcium and
mammographic density was stronger in women with higher IGF-1 and IGFBP3 levels than in
those with low levels. It is plausible that a relationship between vitamin D, calcium and
mammographic density may be limited to premenopausal women, who have substantially
higher levels of IGF-1 and IGFBP-3 than postmenopausal women.46
The mean mammographic density among participants in our population (weighted mean =
7.0%; SD = 9.5%) was considerably lower than in previous studies of postmenopausal women,
31,32 perhaps because our participants were somewhat older than women in other studies.
Studies reporting the strongest relationship between density and vitamin D and/or calcium
intake generally compared women with more extreme mammographic densities.26,30 For
example, Berube and colleages (2004)26 compared risk of having ≥ 70% of the breast with
densities vs. ≤ 30%. Although we assessed this association after stratifying by mammographic
density at baseline and did not find differences across categories, an effect of vitamin D and/
or calcium on breast density may be evident only across a greater range of mammographic
density than observable in our population. We did find evidence of significant effect
modification by age, with vitamin D supplement use associated with lower density in women
50-59 but not in older women. This supports the hypothesis that an effect of vitamin D may
exist only in younger women with higher overall densities.
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Our study assessed the association between vitamin D from dietary or supplemental sources
only and mammographic density, and did not directly take into consideration vitamin D
produced by sunlight exposure. Plasma vitamin D metabolites, mainly 25(OH)D, have been
related to breast cancer risk in several studies10,12-14 but few studies have assessed whether
25(OH)D is related to breast density and results have been inconsistent.34,53,36 For example,
Knight and colleagues (2006)34 did not find serum 25(OH)D levels to be inversely associated
with mammographic density in a study of pre and postmenopausal women. Instead, density
was non-significantly higher in women in the highest quartile of 25(OH)D levels (geometric
mean percent mammographic density = 23.9%) compared to the lowest (21.6%; P = 0.59).
Neither 25(OH)D nor 1,25-dihydroxyvitamin D levels were associated with mammographic
density in a recent analysis in the postmenopausal women.36 In contrast, Brisson and colleagues
(2007)47 observed a strong correlation between mean 25(OH)D levels and mean
mammographic density in a population of premenopausal women, after taking into
consideration seasonal variation in both 25(OH)D levels and mammographic density. In our
population, we did not find that mammographic density or dietary vitamin D intake varied by
season, and observed no evidence of effect modification by season. Additional studies
evaluating the association between 25(OH)D levels and mammographic density in women of
different ages are warranted.
Our study has several additional limitations. Levels of dietary vitamin D and calcium intake
were relatively low in our population. Given the older ages of our participants, and the declines
in subcutaneous vitamin D synthesis and dietary absorption with age,48,49 intake may have
been insufficient to detect an effect on mammographic density. It has been proposed that in
the absence of sunlight exposure, vitamin D intake of 1700-2000 IU per day is necessary to
achieve 25(OH)D levels of 75 nmol/L (30 ng/dL),21 which may be needed to lower breast
cancer risk.50,51 While vitamin D and calcium intake levels in our study are comparable with
those in some previous studies that have observed a relationship with mammographic density
in premenopausal and younger postmenopausal women,26,28,32 higher levels may be needed
to modify mammographic density among older postmenopausal women.
The correlation between total vitamin D and total calcium intakes in our study was high (r for
total calcium vs. vitamin D intake = 0.59, P < 0.001; r for calcium from foods vs. vitamin D
from foods = 0.62, P < 0.001). This high correlation may have affected our ability to evaluate
the independent effects of these two nutrients. However, when we categorized participants
based on intake of both nutrients, we did not find clear evidence that either nutrient was
independently associated with mammographic density. In addition, we were unable to evaluate
the relationship between vitamin D and calcium and the total dense and non-dense area of the
breast, which has been evaluated in some previous studies.28,34
CONCLUSIONS
In summary, we did not observe an association between dietary vitamin D or calcium intake
and mammographic density in our diverse population of postmenopausal women. Additional
studies are needed to further evaluate this relationship in premenopausal women, to consider
the effects of plasma 25(OH)D levels, and to explore issues related to the timing of
mammographic measurements with respect to vitamin D assessment.
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Table 3
Multivariable adjusted mean mammographic density and 95% confidence intervals by total vitamin D and
calcium intake at baseline, Women's Health Initiative Mammogram Density Study (n = 808).
Vitamin D (IU)
Calcium (mg) < 200 200 - 399 ≥ 400
    < 750 7.5 (5.7, 9.2) 2.4 (0.0, 5.7) 2.8 (0.0, 5.7)
    750 - 1199 10.5 (7.2, 13.8) 6.3 (3.9, 8.6) 4.0 (1.1, 6.9)
    ≥ 1200 7.3 (3.0, 11.5) 8.8 (3.9, 13.7) 4.5 (2.5, 6.5)
P int = 0.99
Adjusted for covariates in Model 1: age, race/ethnicity, body mass index, age at menarche, parity, oral contraceptive use and duration, previous HT
use/duration, HT trial randomization assignment, family history of breast cancer, education, alcohol intake, smoking, total calorie intake, physical
activity, Gail risk, and use of multivitamins.













Bertone-Johnson et al. Page 19
Table 4
Multivariable adjusted mean mammographic density by total vitamin D and calcium intake at baseline, stratified
by category of percent density at baseline, Women's Health Initiative Mammogram Density Study (n = 808).
Percent Density (95% Confidence Interval) by Category of Percent Density
Nutrient < 1 % (n = 212) 1 - < 10% (n = 388) ≥ 10% (n = 208)
Total Vitamin D intake (IU/day)
    < 100 0.5 (0.4, 0.6) 3.7 (2.8, 4.6) 18.1 (14.4, 21.8)
    100 – 199 0.6 (0.4, 0.7) 4.5 (3.5, 5.6) 23.3 (20.2, 26.4)
    200 – 399 0.4 (0.2, 0.5) 3.7 (2.9, 4.4) 19.8 (16.0, 23.6)
    ≥ 400 0.5 (0.4, 0.6) 3.6 (2.7, 4.6) 16.9 (12.3, 21.5)
P = 0.16 P = 0.79 P = 0.67
Vitamin D from food sources (IU/day)
    < 100 0.5 (0.4, 0.6) 3.6 (2.9, 4.2) 17.0 (13.7, 20.3)
    100 – 150 0.5 (0.4, 0.6) 4.4 (3.5, 5.2) 20.0 (17.4, 22.7)
    150 – 199 0.5 (0.4, 0.6) 3.9 (3.0, 4.8) 22.6 (19.3, 25.9)
    ≥ 200 0.4 (0.3, 0.5) 3.7 (3.1, 4.3) 20.6 (17.1, 24.1)
P = 0.26 P = 0.50 P = 0.15
Vitamin D from supplements only
    No 0.5 (0.4, 0.6) 3.8 (3.0, 4.5) 22.4 (19.1, 25.7)
    Yes 0.5 (0.3, 0.6) 3.9 (3.1, 4.8) 17.1 (12.7, 21.4)
P = 0.72 P = 0.91 P = 0.09
Total calcium intake (mg/day)
    < 500 0.5 (0.4, 0.6) 3.4 (2.6, 4.3) 20.5 (16.5, 24.4)
    500 – 749 0.6 (0.5, 0.7) 4.2 (3.5, 5.0) 19.8 (16.0, 23.5)
    750 – 999 0.5 (0.4, 0.6) 4.0 (3.2, 4.9) 21.8 (18.2, 25.4)
    ≥ 1000 0.4 (0.4, 0.5) 3.6 (3.0, 4.2) 19.5 (16.8, 22.2)
P = 0.07 P = 0.66 P = 0.85
Calcium from food sources (mg/day)
    < 500 0.5 (0.4, 0.6) 4.0 (3.2, 4.9) 20.3 (16.7, 23.8)
    500 – 649 0.5 (0.4, 0.6) 4.2 (3.5, 4.9) 19.1 (15.0, 23.1)
    650 – 799 0.5 (0.3, 0.6) 3.1 (2.2, 4.0) 18.8 (15.2, 22.5)
    ≥ 800 0.5 (0.4, 0.6) 3.7 (3.2, 4.3) 21.6 (18.8, 24.4)
P = 0.93 P = 0.48 P = 0.27
Calcium from supplements
    None 0.6 (0.5, 0.7) 3.9 (3.3, 4.5) 21.1 (18.6, 23.6)
    < 500 0.4 (0.3, 0.5) 3.8 (3.0, 4.6) 20.2 (16.4, 24.1)
    ≥ 500 0.5 (0.3, 0.6) 3.7 (2.9, 4.6) 19.0 (16.0, 22.0)
P = 0.97 P = 0.48 P = 0.17
Adjusted for covariates in Model 1: age, race/ethnicity, body mass index, age at menarche, parity, oral contraceptive use and duration, previous HT
use/duration, HT trial randomization assignment, family history of breast cancer, education, alcohol intake, smoking, total calorie intake, physical
activity, Gail risk, and use of multivitamins.
Menopause. Author manuscript; available in PMC 2011 November 1.
